Accium BioSciences is a leading provider of accelerator mass spectrometry (AMS) services to the global pharmaceutical and life science industries. Our customers use AMS services to overcome challenges they face in drug development, including assessment of pharmacokinetics, metabolism and mass balance. AMS is an ultrasensitive detection platform capable of quantifying 14C-labeled molecules in the 0.001-100 DPM/mL range. Accium launched the first commercial AMS facility in North America in early 2006. Our services are used by five of the top ten global pharmaceutical companies including Merck, Novartis and Bristol-Myers Squibb. Accium delivers its services through the AMS, Bioanalytical and Quality service units. Customers can mix and match services from any service unit in order to achieve the right outcome at the right cost. This efficient model enables Accium to offer the lowest cost AMS service available anywhere in the world. In addition, Accium's DirectAMS program makes AMS more accessible and more affordable than ever before.